Active Ingredient: Respiratory syncytial virus vaccine
The bivalent, recombinant vaccine is indicated for passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intramuscular, 0.5 milliliters respiratory syncytial virus vaccine, one dose.
A single dose of 0.5 mL should be administered between weeks 24 and 36 of gestation.
The vaccine is for intramuscular injection into the deltoid region of the upper arm.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.